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DNA repair has been regarded as an important barrier to carcinogenesis. The newly dis-
covered field of translesion synthesis (TLS) has made it apparent that mammalian cells
need distinct polymerases to efficiently and accurately bypass DNA lesions. Perturbation
ofTLS polymerase activity by mutation, loss of expression, etc. is expected to result in the
accumulation of mutations in cells exposed to specific carcinogens. Furthermore, several
TLS polymerases can modulate cellular sensitivity to chemotherapeutic agents.TLS genes
and TLS gene variations may thus be attractive pharmacologic and/or pharmacogenetic
targets. We review herein current data with regards to the potential contribution of the
primaryTLS polymerase genes to cancer, their interaction with pharmacologic agents, and
identify areas of interest for further research.
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TRANSLESION DNA SYNTHESIS AND CANCER
Tumors need somatic mutations in order to evolve; yet they
also need efficient DNA replication. Reducing the fidelity of a
human polymerase without affecting its activity [as in the case
of mutations affecting the exonuclease (proofreading) domain of
the replicative human DNA polymerase delta; da Costa et al.,
1995], may be one way that tumors achieve both. Another way
may involve the recently discovered, error-prone (EP) DNA poly-
merases (Kunkel et al., 2003). These polymerases are distributive
enzymes with very low fidelity when copying undamaged DNA
(Kunkel et al., 2003) yet they copy damaged DNA [in a process
called translesion synthesis (TLS)] with much higher efficiency
compared to the replicative DNA enzymes (Goodman, 2002; Pages
and Fuchs, 2002). These findings have led to a model (Goodman,
2002; Pages and Fuchs, 2002) proposing that during DNA replica-
tion the replicative DNA polymerase gets stalled at sites of DNA
damage and it is replaced by an EP polymerase. TLS operates in
addition to other, known pathways of DNA repair (reviewed e.g.,
by Sancar et al., 2004).
Error-prone polymerases lack proofreading activity and can
copy through a specific lesion in either a mutagenic or an accu-
rate manner, depending on the particular lesion, the polymerase
used and the DNA sequence context (Pages and Fuchs, 2002).
For example, the EP polymerase eta (Pol η) performs accurate
TLS in vitro over a thymine–thymine (TT) cyclobutane dimer, a
cis-platinum adduct, an acetyl aminofluorene (AAF) adduct, or
8-oxo guanine yet it results in mutagenic TLS on benzopyrene-
N2-dGuanine (Goodman, 2002). In contrast, polymerase kappa
(Pol κ) can perform accurate TLS on benzopyrene-N2-dGuanine
adducts (Ohashi et al., 2000) yet it results in mutagenic TLS at
8-oxo guanine lesions (Zhang et al., 2000). Thus, a somatic inac-
tivating mutation (genetic contributor) in, e.g., POLK can result
in subsequent mutagenesis of specific genes (based on sequence
context), and eventually cancer, in cells exposed to benzopyrene
(environmental contributor), due to mutagenic TLS repair by the
“wrong” polymerase (e.g., Pol η). Different combinations of EP
polymerases/lesions/sequence contexts can result in distinct sets
of mutated genes and thus specific cancers, without necessarily
affecting DNA synthesis efficiency.
Cancer-inducing mutagenesis resulting from the use of the
wrong EP polymerase has been proposed in order to explain the
phenotype of Xeroderma pigmentosum-variant (XPV) patients
(Kanouche et al., 2002; Kunkel et al., 2003). XPV is a rare inherited
human disorder characterized by increased incidence of sunlight-
induced skin cancers that is caused by inactivating mutations of
POLH (Masutani et al., 1999). In the absence of Pol η. Activity,
XPV cells cannot perform accurate bypass of ultraviolet (UV)-
light induced TT-dimers, and the resulting mutations at TT sites
are thought to cause skin cancer (e.g.,Kanouche et al., 2002; Kunkel
et al., 2003; Stary et al., 2003).
POLB
Human polymerase beta (Pol β) is a monomeric protein of 335
residues (Table 1; Figure 1) that is essential for base excision repair
(BER; Goodman, 2002). BER is one of the major pathways of
DNA repair that removes oxidized and alkylated bases from DNA
(Friedberg, 2003). Pol β is not a classic EP polymerase, yet it causes
67-times more errors than mammalian Pol δ (Table 1; Kunkel et al.,
2003). Pol β often bypasses a DNA lesion by insertion of a com-
plementary nucleotide to an adjacent downstream template site,
resulting in both deletion and substitution errors (Efrati et al.,
1997). Pol β is also involved in meiotic recombination (Kidane
et al., 2010) and is critical for genomic stability in germ cells
(Kidane et al., 2011). Targeted disruption of Pol β in mice resulted
in neonatal lethality (due to respiratory failure) growth retarda-
tion and apoptotic cell death in the developing nervous system
(Sugo et al., 2000), suggesting a role for Pol β in neurogenesis.
Polβ transcription and protein levels are increased in many can-
cer cells (e.g., prostate, breast, colon, ovarian, leukemia; Scanlon
et al., 1989; Louat et al., 2001) and overexpression of Pol β results
in aneuploidy and tumorigenesis in nude immunodeficient mice
(Bergoglio et al., 2002). Moreover, pol β heterozygous mice exhibit
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increased single-stranded DNA breaks, chromosomal aberrations,
and mutagenicity compared to normal animals (Cabelof et al.,
2003). Thus both higher and lower Pol β activity can result in
increased mutagenesis in vivo. These studies suggest that accurate
regulation of Pol β expression may be essential in vivo.Deregulated
Pol βmay cause chromosomal instability either by competing with
replicative polymerases or by TLS over DNA lesions. Indeed, Pol
β exhibits a very low fidelity in DNA synthesis opposite both 8-
oxo-G and 1,2-dihydro-2-oxoadenine (2-OH-A) lesions (Frechet
et al., 2002). These data suggest that Pol β may be an impor-
tant factor in causing some of the genetic changes associated with
cancer.
POLB has been called the “platinum resistance gene” (Iwat-
suki et al., 2009) due to the fact that reduced POLB expression in
colorectal cancer cells results in susceptibility to cisplatin (Iwat-
suki et al., 2009). In contrast, the same experiment performed in
Table 1 | Human translesion synthesis DNA polymerase genes.
Gene Chromosomal
location
Gene structure
(exons)
Protein size
(amino acids)
Error rate
(×10−5)
POLB 8p11 14 335 67
POLH 6p21 11 713 3500
POLK 5q13 15 870 580
POLI 18q21 10 740 24300
Error rate refers to the average single base substitution rate per incorporated
nucleotide during DNA synthesis in vitro, taken from Kunkel et al. (2003). By
comparison, the replicative polymerase Pol δ has an error rate of 1×10−5 (Kunkel
et al., 2003).
mouse embryonic fibroblasts results in sensitivity to oxaliplatin,
but not cisplatin (Yang et al., 2010). These differences may be
due to tissue- and/or development- specific factors. Higher Pol β
expression also correlated with poorer colorectal cancer prognosis
(Iwatsuki et al., 2009), underscoring the significance of this gene
for chemotherapy.
GERMLINE SINGLE NUCLEOTIDE POLYMORPHISMS OF POLB
Seven non-synonymous DNA substitutions of POLB have been
described in dbSNP in normal individuals1. These single-
nucleotide polymorphisms (SNPs) display minor allele frequen-
cies (MAF) of 2–10%. Four of these variants have been vali-
dated, including three common SNPs (i.e., SNPs with MAF> 1%;
Table 2). Two of these variants have been characterized biochemi-
cally thus far. The p.R137Q variant (refers to rs12678588; Table 2)
displayed abnormal BER activity through both decreased cat-
alytic activity and aberrant interaction with PCNA (Guo et al.,
2009). The p.P242R variant (refers to rs3136797; Table 2) dis-
played altered fidelity of DNA synthesis for all possible dNTP
misincorporations across a single-nucleotide gapped template (An
et al., 2011). Given the known mechanistic effects of the stud-
ied missense variants of Pol β (e.g., Guo et al., 2009; An et al.,
2011), it is likely that some of the yet uncharacterized non-
synonymous nucleotide substitutions of Pol β affect polymerase
function.
SOMATIC MUTATIONS OF POLB IN TUMORS
Table 2 shows that somatic Pol β variants are present in 15–
75% of tumors analyzed to date (e.g., Starcevic et al., 2004;
1http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?locusId= 5423
FIGURE 1 | Structural comparisons of TLS enzymes. Major functional domains are indicated. Not drawn to scale. Key: PCNA, proliferating cell nuclear antigen.
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Table 2 | Genetic variants of translesion synthesis DNA polymerase
genes.
Gene Common validated
ns-SNPs*(MAF;
population)
Somatic
mutations
(freq; tissue)
Citation**
POLB rs12678588 (0.04; MEX) many (15–75%;
many tissues)
Starcevic et al.
(2004), Makridakis
et al. (2009)
rs56121607 (0.02; CH)
rs3136797 (0.02; AA)
POLH rs2307456 (0.03; MEX) 7 (1.5–12%;
melanoma,
breast, prostate)
Makridakis et al.
(2009), Di Lucca
et al. (2009),
Sjöblom et al. (2006)
rs35675573 (0.02;YRI)
rs9296419 (0.1; CH)
rs9333554 (0.07;YRI)
rs9333555 (0.04; GIH)
rs6941583 (0.411; LWK)
POLK rs35257416 (0.03; AA) 6 (1–100%;
prostate,
ovarian, kidney)
Makridakis et al.
(2009), Cancer
Genome Atlas
Research Network
(2011), Dalgliesh
et al. (2010)
rs3822587 (0.05; CH)
rs5744716 (0.03; MEX)
POLI rs3218786 (0.04; CAU) 3 (1–33%;
ovarian, kidney)
Cancer Genome
Atlas Research
Network (2011),
Dalgliesh et al. (2010)
rs8305 (0.380; CAU)
*Common=minor allele frequency>1% (dbSNP Build 134).
**Refers to somatic mutations.
Key: MAF, the highest minor allele frequency reported in dbSNP for any
racial/ethnic group; freq, % patients with a somatic polymerase mutation; AA,
African American; CAU, Caucasian American; CH, Han Chinese; GIH, Gujarati
Indians; LWK, Luhya inWebuye, Kenya; MEX, Mexican American; YRI, Yoruba.
Makridakis et al., 2009). Functional analysis has implicated many
of these variants in cancer etiology and/or progression. Specifi-
cally, the p.K27N and the triple mutant (p.P261L/T292A/I298T)
variants reduced catalytic efficiency, while the p.E123K, p.E232K,
p.P242R, p.E216K, and p.M236L variants altered the fidelity of
DNA synthesis at steady-state conditions (An et al., 2011). Fur-
thermore, overexpression of either the p.K289M or p.I260M
Pol β variants in mouse fibroblasts, resulted in cellular trans-
formation (Dalal et al., 2005; Sweasy et al., 2005). The find-
ing that the transformed phenotype remained after expression
of these variants had ceased in these cells, suggests that trans-
formation occurred after further mutations induced by the Pol
β variant, thereby supporting the mutagenic model for cancer
etiology proposed above. Given the high frequency of func-
tional somatic POLB mutations in tumors, and the correlation
of POLB expression with survival and drug susceptibility, fur-
ther pharmacologic and pharmacogenetic studies will be highly
beneficial.
POLH
Pol η belongs to the Y polymerase family (which includes REV1,
Pol κ, and Pol ι; Figure 1). In humans, Pol η is encoded by
the POLH gene, also known as XPV gene, because it was found
mutated in a fraction of patients suffering from XP disease that
did not carry mutations in nucleotide excision repair (NER) genes
(see above; Johnson et al., 1999a; Masutani et al., 1999). POLH
lies on chromosomal band 6p21 (Table 1). Loss of Pol η results
in a reduced ability to copy DNA containing a very common
form of sunlight-induced damage, TT-dimers (Johnson et al.,
1999b; Masutani et al., 1999). Pol η can bypass these lesions with
high accuracy and processivity, but is less processive and more
inaccurate on undamaged DNA templates (Matsuda et al., 2001;
Washington et al., 2001). In addition to pyrimidine dimmers, Pol
η can efficiently bypass a wide variety of DNA lesions, in both EP
and error-free manner, including mitomycin C adducts (Zheng
et al., 2003), and cisplatin adducts (Albertella et al., 2005; Alt et al.,
2007).
Pol η shows higher catalytic efficiency than Pol β when bypass-
ing cisplatin adducts (Chaney et al., 2005). Furthermore, Pol η
downregulation results in increased sensitivity to cisplatin (Chen
et al., 2006). Not surprisingly, high POLH expression associ-
ated with significantly shorter survival, in a group of platinum
treated non-small cell lung cancer patients (Ceppi et al., 2009).
Moreover, the kinase inhibitor LY294002 enhanced the killing
of cells deficient in Pol η, synergistically with the chemother-
apeutic agent doxorubicin (Moraes et al., 2012) underscor-
ing the ability of Pol η to regulate cellular response to these
agents.
Pol η can also modulate cellular response to anticancer nucle-
oside analogs. Indeed, Pol η efficiently extends from both arabi-
nosylcytocine (AraC) and gemcitabine containing 3′ DNA ends,
and reduces cellular sensitivity to both of these nucleoside analogs
(Chen et al., 2006). These data make Pol η an attractive candidate
for pharmacogenetic studies.
GERMLINE SNPs OF POLH
Many missense skin cancer-predisposing Pol η mutations have
been identified in XPV patients (reviewed in Gratchev et al., 2003).
In addition, 37 non-synonymous POLH substitutions have been
described in dbSNP in normal individuals2. These SNPs display
MAF of 0.3–11.4%. Twelve of these SNPs have been validated,
including common SNPs (Table 2). One of the common non-
synonymous POLH variants, rs9333555 (Table 2) was found to be
significantly associated with melanoma risk (OR= 1.84; Di Lucca
et al., 2009). This finding was confirmed in a meta-analysis (Di
Lucca et al., 2009). Thus, other types of skin cancer are also good
candidates for the identification of POLH cancer-predisposing
alleles.
SOMATIC MUTATIONS OF POLH IN TUMORS
No somatic mutations of Polηwere found in two screens of 15 and
17 basal/squamous cell carcinomas of the skin (Glick et al., 2006;
Flanagan et al., 2007). However, three missense POLH mutations
were identified in three out of 201 melanoma patients, and these
mutations were absent in 176 healthy controls (Di Lucca et al.,
2009). These results warranty a more careful examination of POLH
for somatic mutations in large numbers of skin tumors. Further-
more, biochemical analysis of the cancer-associated variants will
2http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?locusId= 5429
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be necessary in order to distinguish tumor “drivers” from mere
passengers of tumor evolution. Interestingly, the same somatic
POLH mutation, p.G153D, was identified by two independent
studies, in a small subset (2–9%) of breast tumors3 (Sjöblom
et al., 2006). By screening only one exon of the POLH gene,
we identified three missense somatic mutations in two out of
26 prostate tumors (Makridakis et al., 2009). One of these three
Pol η mutations that we identified is in glycine-263 (Makridakis
et al., 2009). Homozygous missense mutation of Pol η glycine-
263 has been reported in an XPV patient (Broughton et al.,
2002). These data suggest that Pol η may play a role in tumor
progression in different types of cancer. Given the protective
role of Pol η with various types of chemotherapeutic drugs (see
above), further molecular genetic and pharmacogenetic studies
are warrantied.
POLK
Pol κ (Figure 1) is a Y polymerase family enzyme encoded by the
POLK gene, which lies on chromosomal band 5q13 in humans
(Table 1). Pol κ is the human polymerase mostly similar to the
E. coli polymerase pol IV/DinB (Hubscher et al., 2002). Pol κ can
bypass benzo[a]pyrene diol epoxide (BPDE) adducts on the N2 of
guanine in an error-free manner (Rechkoblit et al., 2002; Suzuki
et al., 2002). Pol κ can also efficiently bypass AAF-guanine and
ethenodeoxy-adenosine adducts, but in an EP manner (Goodman,
2002). Pol κ expression was diminished in rat mammary carci-
noma cell lines and primary mammary carcinomas in comparison
to that of the normal tissues (Pan et al., 2005). In contrast, Pol κ is
overexpressed in lung cancer (O-Wang et al., 2001). This discrep-
ancy of differential expression in distinct types of tumors, may be
an adaptation to different mutagen and/or adduct concentrations
in distinct human tissues.
Mouse embryonic stem cells genetically depleted of Pol κ are
highly sensitive to both killing and mutagenesis induced by ben-
zopyrene, but not to UV-light or X-rays (Ogi et al., 2002). Expres-
sion of the mouse pol κ gene is under the control of the aryl
hydrocarbon receptor, an important factor for the metabolic acti-
vation of benzopyrene to BPDE in mammalian cells (Ogi et al.,
2001). These results suggest that Pol k may function in vivo in
error-free TLS of lesions generated by polycyclic aromatic hydro-
carbons (PAH), such as BPDE. Thus Pol κ inactivation may result
in PAH-induced mutagenesis and cancer in cells exposed to PAH.
Furthermore, ectopic Pol κ overexpression induced aneuploidy,
DNA strand breaks, and tumorigenesis in nude mice (Bavoux et al.,
2005). The POLK gene was also shown to display loss of heterozy-
gosity in non-squamous lung carcinomas compared to adjacent
normal tissue (Bavoux et al., 2005). Thus, both the increase and
decrease of Pol κ steady-state levels can promote a malignant
phenotype.
In addition, Pol κ is up-regulated in mouse and human cells by
a p53-dependent pathway, in response to various DNA-damaging
agents (Velasco-Miguel et al., 2003), and also in response to
functional loss of p53 (Wang et al., 2004). The involvement of
3http://www.sanger.ac.uk/perl/genetics/CGP/cosmic?action=mut_summary&id=
13899
both p53-dependent and p53-independent pathways for Pol κ
upregulation suggests that Polκmay play an important physiologic
role in guarding genome stability.
Pol κ is able to bypass tamoxifen-derived DNA adducts more
efficiently and accurately than Pol η (Yasui et al., 2006). Thus
pharmacologic and/or pharmacogenetic studies with tamoxifen
and tumor survival will be highly beneficial.
GERMLINE SNPs OF POLK
Forty-seven non-synonymous POLK substitutions have been
described in dbSNP in normal individuals4. These SNPs display
MAF of 1.4–1.8%. Eighteen of these SNPs have been validated,
including some common SNPs (Table 2). None of these SNPs have
been evaluated biochemically for their effect on enzyme activity.
However, analysis of 62 DNA repair genes identified two non-
coding POLK SNPs that were significantly associated with lung
cancer risk (Michiels et al., 2007). Moreover, eQTL analysis by the
GTEx web browser5, indicates that the trans-eQTL SNP rs1828591
significantly associates with POLK gene expression in the liver
(Schadt et al., 2008). These data underscore the potential signif-
icance of both coding and non-coding POLK SNPs in different
types of cancer.
SOMATIC MUTATIONS OF POLK IN TUMORS
Three distinct somatic missense POLK mutations have been
reported so far in tumors by the Sanger Institute: one in ovar-
ian cancer (p.R48I, in two out of two patients) and two in kidney
cancer6 (p.F286S and p.M364L, in 1% of the patients). We also
identified three somatic POLK mutations in prostate tumors, by
screening two exons in 26 patients (Makridakis et al., 2009). One of
these somatic substitutions changes the predicted invariant Ade-
nine of intron five of POLK where the lariat forms (Makridakis
et al., 2009), and thus may result in abnormal splicing. The other
two somatic POLK mutations are missense (Makridakis et al.,
2009). Both missense substitutions that we identified inPol κ are in
threonine-205 (Makridakis et al., 2009). The homologous residue
in Pol η of threonine-205 of Pol κ, is threonine-122 (Boudsocq
et al., 2002). Germline missense mutation of threonine-122 of
human Pol η has been reported in an XPV patient (Broughton
et al., 2002).
Thus, three of the somatic missense mutations that we iden-
tified in the Y-family polymerase genes POLK and POLH are
in (or are in residues homologous to) residues of Pol η previ-
ously associated with XPV. This finding can be explained by two
possibilities: (a) that these are mutational hotspots, or (b) that
these mutations play a role in carcinogenesis. We favor the lat-
ter scenario. This explanation however generates an interesting
question. XPV patients are born with a Pol η mutation. If the
same mutation that is involved in prostate cancer etiology is also
present in all of the cells of some XPV patients, then why do
these patients get only skin cancer and not prostate (or other
4http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?locusId= 51426
5http://www.ncbi.nlm.nih.gov/gtex/GTEX2/gtex.cgi
6http://www.sanger.ac.uk/perl/genetics/CGP/cosmic?action= bygene&ln=POLK&
start= 1&end= 871&coords=AA:AA
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type of) cancer? The most likely explanation is different environ-
mental exposure: XPV patients are inevitably exposed to sunlight,
but not necessarily to prostate cancer-inducing environmental
mutagens (the prostate gland is too deep inside the body to be
affected by sunlight, and Pol η may be important for repairing
DNA damage relevant to the prostate, such as oxidation dam-
age). An alternative explanation though is that Pol η mutation
maybe sufficient for skin carcinogenesis, but that an additional
(presumably rare) molecular event is necessary for prostate car-
cinogenesis. Regardless, these data suggest that EP polymerase
gene mutations may be common and prevalent in prostate cancer
tissue.
POLI
The human POLI gene lies in chromosomal band 18q21, and
encodes for Polymerase ι (Figure 1). Pol ι is able to bypass many
DNA lesions, such as pyrimidine dimers, oxidative damage, and
PAH adducts, but it cannot extend after the intial incorporation
(Vaisman and Woodgate, 2001; Frank et al., 2002; Wang et al.,
2007). Thus, the utilization of Pol ι in TLS in vivo depends on an
extension polymerase, such as Pol ζ (Johnson et al., 2000; Guo et al.,
2001). The fidelity of Pol ι on undamaged DNA is generally low
(Table 1) but very variable: error frequencies of 10−4 to 10−5 are
observed opposite template A, 10−1 to 10−2 opposite templates G
and C, while it prefers to incorporate the wrong nucleotide (mainly
G) opposite template T (Zhang et al., 2000; Haracska et al., 2001;
Tissier et al., 2000). Pol ι is able to perform BER in vitro (Bebenek
et al., 2001). A possible explanation for this unusual preference of
Pol ι opposite template T is that during in vivo BER, Pol ι would
insert G opposite a template T that had been generated by deam-
ination of a 5-methylated C, thus preventing C>T transitions at
CpG islands.
Pol ι expression is elevated in breast cancer cells and corre-
lates with a significant decrease in DNA synthesis fidelity (Yang
et al., 2004). Furthermore, UV treatment of breast cancer cells
additionally increased Pol ι expression, while a reduction in muta-
tion frequency was shown after Pol ι was immunodepleted from
nuclear extracts of the same breast cancer cells (Yang et al., 2004).
These data suggest that Pol ι may play a role in breast cancer
development and/or progression.
GERMLINE SNPs OF POLI
Forty-nine non-synonymous POLI substitutions have been
described in dbSNP in normal individuals7. These SNPs display
MAF of 0.1–22%). Twenty-three of these SNPs have been vali-
dated, including common variants (Table 2). None of these SNPs
have been evaluated biochemically for their effect on enzyme activ-
ity. However, a single-nucleotide polymorphism in POLI (rs8305),
correlated with a significantly higher risk of both lung adeno-
carcinoma and squamous cell carcinoma (Sakiyama et al., 2005).
Furthermore, another POLI SNP (rs3218786), was significantly
associated with TMPRSS2-ERG fusion-positive prostate tumors
(Luedeke et al., 2009).
7http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?locusId= 11201
SOMATIC MUTATIONS OF POLI IN TUMORS
Three distinct somatic missense POLI mutations have been
reported so far in tumors by the Sanger Institute: two in ovar-
ian cancer (p.R28T, in one out of three patients; and p.K271E,
in another patient) and one in kidney cancer8 (p.D306V, in 1% of
the patients). These data suggest the need for more comprehensive
analysis of tumor tissues.
OTHER TLS POLYMERASES
In addition to the polymerases reviewed above, other low-
fidelity DNA polymerases have TLS synthesis abilities (reviewed
by Moon et al., 2007). The Y-family polymerase REV1 has
been proposed to act as a scaffold for other TLS enzymes,
such as Pol η and Pol κ (Tissier et al., 2004). Knockdown of
REV1 mRNA results in a significant reduction of UV-irradiation
induced mutagenesis (Clark et al., 2003). Two distinct non-
synonymous REV1 SNPs have been associated with cervical
cancer risk (He et al., 2008). Furthermore, six missense and
one nonsense REV1 substitutions have been reported by the
Sanger Institute, in a minority of tumors9. These data imply the
need for further interrogation of REV1 in cancer etiology and
progression.
Members of the X family of DNA polymerases (such as
Pol λ and Pol µ), can perform TLS with various efficiencies,
depending on the lesion (Blanca et al., 2004; Moon et al., 2007).
These polymerases display the second lowest replication fidelity
among the six major DNA polymerase families (after the Y-
family; Kunkel, 2004). Furthermore, Pol θ (a family A member),
exhibits lower replication fidelity relative to the other A family
members and has been suggested to participate in TLS in vivo
(Arana et al., 2008). However, these non-Y-family polymerases
have other primary functions in vivo, independent of TLS, such
as non-homologous end joining (X family polymerases). Accord-
ingly, we focused in this review mostly on the Y-family poly-
merases, which primarily function in lesion bypass (Friedberg
et al., 2005).
CONCLUSION
Translesion synthesis is the newest and less characterized path-
way of DNA repair. It involves DNA polymerases that facilitate
DNA replication (and thus cell division) by efficiently bypassing
various DNA lesions in a relatively error-free manner. TLS poly-
merase gene expression, mutation, and regulation, is important
for cancer etiology and treatment. Current pharmacologic data
regarding the interactions of TLS polymerases with various muta-
gens and chemotherapeutic drugs underscore the significance of
further pharmacologic and pharmacogenetic research.
ACKNOWLEDGMENTS
Nick M. Makridakis is supported by grant number P20GM103518,
from the National Institutes of Health, and PC094628 from the
Department of Defense.
8http://www.sanger.ac.uk/perl/genetics/CGP/cosmic?action= bygene&ln=POLI&
start= 1&end= 716&coords=AA:AA
9http://www.sanger.ac.uk/perl/genetics/CGP/cosmic?action= bygene&ln=REV1&
start= 1&end= 1252&coords=AA:AA
www.frontiersin.org September 2012 | Volume 3 | Article 174 | 5
Makridakis and Reichardt Translesion DNA polymerases and cancer
REFERENCES
Albertella, M. R., Green, C. M.,
Lehmann, A. R., and O’Connor, M.
J. (2005). A role for polymerase eta
in the cellular tolerance to cisplatin-
induced damage. Cancer Res. 65,
9799–9806.
Alt, A., Lammens, K., Chiocchini, C.,
Lammens, A., Pieck, J. C., Kuch,
D., Hopfner, K. P., and Carell, T.
(2007). Bypass of DNA lesions gen-
erated during anticancer treatment
with cisplatin by DNA polymerase
eta. Science 318, 967–970.
An, C. L., Chen, D., and Makridakis, N.
M. (2011). Systematic biochemical
analysis of somatic missense muta-
tions in DNA polymerase β found
in prostate cancer reveal alteration
of enzymatic function. Hum. Mutat.
32, 415–423.
Arana, M., Seki, E. M., Wood, R. D.,
Rogozin, I. B., and Kunkel, T. A.
(2008). Low-fidelity DNA synthesis
by human DNA polymerase theta.
Nucleic Acids Res. 36, 3847–3856.
Bavoux, C., Leopoldino, A. M.,
Bergoglio, V., O-Wang, J., Ogi, T.,
Bieth, A., Judde, J. G., Pena, S.
D., Poupon, M. F., Helleday, T.,
Tagawa, M., Machado, C., Hoff-
mann, J. S., and Cazaux, C. (2005).
Up-regulation of the error-prone
DNA polymerase {kappa} promotes
pleiotropic genetic alterations and
tumorigenesis. Cancer Res. 65,
325–330.
Bebenek, K., Tissier, A., Frank, E. G.,
McDonald, J. P., Prasad, R., Wilson,
S. H., Woodgate, R., and Kunkel,
T. A. (2001). 5′-Deoxyribose phos-
phate lyase activity of human DNA
polymerase iota in vitro. Science 291,
2156–2159.
Bergoglio, V., Pillaire, M. J., Lacroix-
Triki, M., Raynaud-Messina, B.,
Canitrot, Y., Bieth, A., Garès, M.,
Wright, M., Delsol, G., Loeb, L.
A., Cazaux, C., and Hoffmann, J.
S. (2002). Deregulated DNA poly-
merase beta induces chromosome
instability and tumorigenesis. Can-
cer Res. 62, 3511–3514.
Blanca, G., Villani, G., Shevelev, I.,
Ramadan, K., Spadari, S., Hubscher,
U., and Maga, G. (2004). Human
DNA polymerases lambda and beta
show different efficiencies of transle-
sion DNA synthesis past abasic
sites and alternative mechanisms for
frameshift generation. Biochemistry
43, 11605–11615.
Boudsocq, F., Ling, H., Yang, W., and
Woodgate, R. (2002). Structure-
based interpretation of missense
mutations in Y-family DNA poly-
merases and their implications for
polymerase function and lesion
bypass. DNA Repair (Amst.) 1,
343–358.
Broughton, B. C., Cordonnier, A., Klei-
jer, W. J., Jaspers, N. G., Fawcett,
H., Raams, A., Garritsen, V. H.,
Stary, A., Avril, M. F., Boudsocq, F.,
Masutani, C., Hanaoka, F., Fuchs,
R. P., Sarasin, A., and Lehmann,
A. R. (2002). Molecular analysis of
mutations in DNA polymerase eta
in xeroderma pigmentosum-variant
patients. Proc. Natl. Acad. Sci. U.S.A.
99, 815–820.
Cabelof, D. C., Guo, Z., Raffoul, J.
J., Sobol, R. W., Wilson, S. H.,
Richardson, A., and Heydari, A. R.
(2003). Base excision repair defi-
ciency caused by polymerase beta
haploinsufficiency: accelerated DNA
damage and increased mutational
response to carcinogens. Cancer Res.
63, 5799–5807.
Cancer Genome Atlas Research Net-
work. (2011). Integrated genomic
analyses of ovarian carcinoma.
Nature. 474, 609–615.
Ceppi, P., Novello, S., Cambieri, A.,
Longo, M., Monica, V., Lo Iacono,
M., Giaj-Levra, M., Saviozzi, S.,
Volante, M., Papotti, M., and
Scagliotti, G. (2009). Polymerase
eta mRNA expression predicts sur-
vival of non-small cell lung can-
cer patients treated with platinum-
based chemotherapy. Clin. Cancer
Res. 15, 1039–1045.
Chaney, S. G., Campbell, S. L., Bas-
sett, E., and Wu, Y. (2005). Recogni-
tion and processing of cisplatin- and
oxaliplatin-DNA adducts. Crit. Rev.
Oncol. Hematol. 53, 3–11.
Chen, Y. W., Cleaver, J. E., Hanaoka,
F., Chang, C. F., and Chou, K. M.
(2006). A novel role of DNA poly-
merase eta in modulating cellu-
lar sensitivity to chemotherapeutic
agents. Mol. Cancer Res. 4, 257–265.
Clark, D. R., Zacharias, W., Panaitescu,
L., and McGregor, W. G. (2003).
Ribozyme-mediated REV1 inhibi-
tion reduces the frequency of UV-
induced mutations in the human
HPRT gene. Nucleic Acids Res. 31,
4981–4988.
da Costa, L. T., Liu, B., el-Deiry,
W., Hamilton, S. R., Kinzler, K.
W., Vogelstein, B., Markowitz, S.,
Willson, J. K., de la Chapelle, A.,
Downey, K. M., and So, A. G. (1995).
Polymerase delta variants in RER
colorectal tumours. Nat. Genet. 9,
10–11.
Dalal, S., Hile, S., Eckert, K. A., Sun, K.
W., Starcevic, D., and Sweasy, J. B.
(2005). Prostate-cancer-associated
I260M variant of DNA polymerase
beta is a sequence-specific mutator.
Biochemistry 44, 15664–15673.
Dalgliesh, G. L., Furge, K., Greenman,
C., Chen, L., Bignell, G., Butler,
A., Davies, H., Edkins, S., Hardy,
C., Latimer, C., Teague, J., Andrews,
J., Barthorpe, S., Beare, D., Buck,
G., Campbell, P. J., Forbes, S., Jia,
M., Jones, D., Knott, H., Kok, C.
Y., Lau, K. W., Leroy, C., Lin, M.
L., McBride, D. J., Maddison, M.,
Maguire, S., McLay, K., Menzies,
A., Mironenko, T., Mulderrig, L.,
Mudie, L., O’Meara, S., Pleasance,
E., Rajasingham, A., Shepherd, R.,
Smith, R., Stebbings, L., Stephens, P.,
Tang, G., Tarpey, P. S., Turrell, K.,
Dykema, K. J., Khoo, S. K., Petillo,
D., Wondergem, B., Anema, J., Kah-
noski, R. J., Teh, B. T., Stratton, M.
R., and Futreal, P. A. (2010). Sys-
tematic sequencing of renal carci-
noma reveals inactivation of his-
tone modifying genes. Nature 463,
360–363.
Di Lucca, J., Guedj, M., Lacapère, J.
J., Fargnoli, M. C., Bourillon, A.,
Dieudé, P., Dupin, N., Wolken-
stein, P., Aegerter, P., Saiag, P.,
Descamps, V., Lebbe, C., Basset-
Seguin, N., Peris, K., Grandchamp,
B., and Soufir, N. (2009). Variants of
the xeroderma pigmentosum vari-
ant gene (POLH) are associated with
melanoma risk. Eur. J. Cancer 45,
3228–3236.
Efrati, E., Tocco, G., Eritja, R., Wil-
son, S. H., and Goodman, M. F.
(1997). Abasic translesion synthe-
sis by DNA polymerase beta vio-
lates the “A-rule.” Novel types of
nucleotide incorporation by human
DNA polymerase beta at an abasic
lesion in different sequence contexts.
J. BiolChem. 272, 2559–2569.
Flanagan, A. M., Rafferty, G., O’Neill,
A., Rynne, L., Kelly, J., McCann, J.,
and Carty, M. P. (2007). The human
POLH gene is not mutated, and is
expressed in a cohort of patients
with basal or squamous cell carci-
noma of the skin. Int. J. Mol. Med.
19, 589–596.
Frank, E. G., Sayer, J. M., Kroth,
H., Ohashi, E., Ohmori, H.,
Jerina, D. M., and Woodgate,
R. (2002). Translesion repli-
cation of benzo[a]pyrene and
benzo[c]phenanthrene diol epoxide
adducts of deoxyadenosine and
deoxyguanosine by human DNA
polymerase iota. Nucleic Acids Res.
30, 5284–5292.
Frechet, M., Canitrot, Y., Bieth, A.,
Dogliotti, E., Cazaux, C., and Hoff-
mann, J. S. (2002). Deregulated
DNA polymerase beta strengthens
ionizing radiation-induced nucleo-
tidic and chromosomal instabilities.
Oncogene 21, 2320–2327.
Friedberg, E. C. (2003). DNA damage
and repair. Nature 421, 436–440.
Friedberg, E. C., Walker, G. C., Siede,
W., Wood, R. D., Schultz, R. A., and
Ellenberger, T. (2005). DNA Repair
andMutagenesis, 2nd Edn. Washing-
ton, DC: ASM Press.
Glick, E., White, L. M., Elliott, N. A.,
Berg, D., Kiviat, N. B., and Loeb, L.
A. (2006). Mutations in DNA poly-
merase eta are not detected in squa-
mous cell carcinoma of the skin. Int.
J. Cancer 119, 2225–2227.
Goodman, M. F. (2002). Error-prone
repair DNA polymerases in prokary-
otes and eukaryotes. Annu. Rev.
Biochem. 71, 17–50.
Gratchev, A., Strein, P., Utikal, J., and
Sergij, G. (2003). Molecular genet-
ics of xeroderma pigmentosum vari-
ant. Exp. Dermatol. 12, 529–536.
[Review].
Guo, D., Wu, X., Rajpal, D. K., Taylor,
J. S., and Wang, Z. (2001). Transle-
sion synthesis by yeast DNA poly-
merase zeta from templates contain-
ing lesions of ultraviolet radiation
and acetylaminofluorene. Nucleic
Acids Res. 29, 2875–2883.
Guo, Z., Zheng, L., Dai, H., Zhou, M.,
Xu, H., and Shen, B. (2009). Human
DNA polymerase beta polymor-
phism, Arg137Gln, impairs its poly-
merase activity and interaction with
PCNA and the cellular base excision
repair capacity. Nucleic Acids Res. 37,
3431–3441.
Haracska, L., Johnson, R. E., Unk, I.,
Phillips, B. B., Hurwitz, J., Prakash,
L., and Prakash, S. (2001). Targeting
of human DNA polymerase iota to
the replication machinery via inter-
action with PCNA. Proc. Natl. Acad.
Sci. U.S.A. 98, 14256–14261.
He, X., Ye, F., Zhang, J., Cheng, Q.,
Shen, J., and Chen, H. (2008). REV1
genetic variants associated with the
risk of cervical carcinoma. Eur. J.
Epidemiol. 23, 403–409.
Hubscher, U., Maga, G., and Spadari,
S. (2002). Eukaryotic DNA poly-
merases. Annu. Rev. Biochem. 71,
133–163.
Iwatsuki, M., Mimori, K., Yokobori, T.,
Tanaka, F., Tahara, K., Inoue, H.,
Baba, H., and Mori, M. (2009).
A platinum agent resistance gene,
POLB, is a prognostic indicator in
colorectal cancer. J. Surg. Oncol. 100,
261–266.
Johnson, R. E., Kondratick, C. M.,
Prakash, S., and Prakash, L. (1999a).
hRAD30 mutations in the variant
form of xeroderma pigmentosum.
Science 285, 263–265.
Johnson, R. E., Prakash, S., and Prakash,
L. (1999b). Efficient bypass of a
thymine-thymine dimer by yeast
Frontiers in Genetics | Pharmacogenetics and Pharmacogenomics September 2012 | Volume 3 | Article 174 | 6
Makridakis and Reichardt Translesion DNA polymerases and cancer
DNA polymerase, Poleta. Science
283, 1001–1004.
Johnson, R. E., Washington, M. T.,
Haracska, L., Prakash, S., and
Prakash, L. (2000). Eukaryotic poly-
merases iota and zeta act sequen-
tially to bypass DNA lesions. Nature
406, 1015–1019.
Kanouche, P., Fernandez de Henestrosa,
A. R., Coull, B., Vidal, A. E., Gray,
C., Zicha, D., Woodgate, R., and
Lehmann, A. R. (2002). Localization
of DNA polymerases η and ι to the
replication machinery is tightly co-
ordinated in human cells. EMBO J.
21, 6246–6256.
Kidane, D., Dalal, S., Keh, A., Liu,Y., Zel-
terman, D., and Sweasy, J. B. (2011).
DNA polymerase beta is critical for
genomic stability of sperm cells.
DNA Repair (Amst.) 10, 390–397.
Kidane, D., Jonason, A. S., Gorton, T.
S., Mihaylov, I., Pan, J., Keeney, S.,
de Rooij, D. G., Ashley, T., Keh,
A., Liu, Y., Banerjee, U., Zelter-
man, D., and Sweasy, J. B. (2010).
DNA polymerase beta is critical for
mouse meiotic synapsis.EMBOJ. 29,
410–423.
Kunkel, T. A. (2004). DNA replica-
tion fidelity. J. Biol. Chem. 279,
16895–16898.
Kunkel, T. A., Pavlov, Y. I., and Bebenek,
K. (2003). Functions of human DNA
polymerases eta, kappa and iota sug-
gested by their properties, includ-
ing fidelity with undamaged DNA
templates. DNA Repair (Amst.) 2,
135–149.
Louat, T., Servant, L., Rols, M.
P., Bieth, A., Teissie, J., Hoff-
mann, J. S., and Cazaux, C.
(2001). Antitumor activity of 2′,3′-
dideoxycytidine nucleotide analog
against tumors up-regulating DNA
polymerase beta. Mol. Pharmacol.
60, 553–558. [Erratum in:Mol. Phar-
macol. 2002. 61, 1263].
Luedeke, M., Linnert, C. M., Hofer, M.
D., Surowy, H. M., Rinckleb, A. E.,
Hoegel, J., Kuefer, R., Rubin, M. A.,
Vogel, W., and Maier, C. (2009).
Predisposition for TMPRSS2-ERG
fusion in prostate cancer by vari-
ants in DNA repair genes. Can-
cer Epidemiol. Biomarkers Prev. 18,
3030–3035.
Makridakis, N. M., Phipps, T., Srivas-
tav, S., and Reichardt, J. K. (2009).
PCR-free method detects high fre-
quency of genomic instability in
prostate cancer.NucleicAcids Res. 37,
7441–7446.
Masutani, C., Kusumoto, R.,Yamada,A.,
Dohmae, N., Yokoi, M., Yuasa, M.,
Araki, M., Iwai, S., Takio, K., and
Hanaoka, F. (1999). The XPV (xero-
derma pigmentosum variant) gene
encodes human DNA polymerase
eta. Nature 399, 700–704.
Matsuda, T., Bebenek, K., Masutani,
C., Rogozin, I. B., Hanaoka, F., and
Kunkel, T. A. (2001). Error rate and
specificity of human and murine
DNA polymerase eta. J. Mol. Biol.
312, 335–346.
Michiels, S., Danoy, P., Dessen, P., Bera,
A., Boulet, T., Bouchardy, C., Lath-
rop, M., Sarasin, A., and Benhamou,
S. (2007). Polymorphism discovery
in 62 DNA repair genes and hap-
lotype associations with risks for
lung and head and neck cancers.
Carcinogenesis 28, 1731–1739.
Moon, A. F., Garcia-Diaz, M., Batra, V.
K.,Beard,W. A.,Bebenek,K.,Kunkel,
T. A., Wilson, S. H., and Pedersen,
L. C. (2007). The X family portrait:
structural insights into biological
functions of X family polymerases.
DNA Repair (Amst.) 6, 1709–1725.
Moraes, M. C., de Andrade, A. Q., Car-
valho, H., Guecheva, T., Agnoletto,
M. H., Henriques, J. A., Sarasin,
A., Stary, A., Saffi, J., and Menck,
C. F. (2012). Both XPA and DNA
polymerase eta are necessary for
the repair of doxorubicin-induced
DNA lesions. Cancer Lett. 314,
108–118.
Ogi, T., Mimura, J., Hikida, M.,
Fujimoto, H., Fujii-Kuriyama, Y.,
and Ohmori, H. (2001). Expres-
sion of human and mouse genes
encoding polkappa: testis-specific
developmental regulation and AhR-
dependent inducible transcription.
Genes Cells 6, 943–953.
Ogi, T., Shinkai, Y., Tanaka, K., and
Ohmori, H. (2002). Polkappa pro-
tects mammalian cells against the
lethal and mutagenic effects of
benzo[a]pyrene. Proc. Natl. Acad.
Sci. U.S.A. 99, 15548–15553.
Ohashi, E., Ogi, T., Kusumoto, R.,
Iwai, S., Masutani, C., Hanaoka, F.,
and Ohmori, H. (2000). Error-prone
bypass of certain DNA lesions by
the human DNA polymerase kappa.
Genes Dev. 14, 1589–1594.
O-Wang, J., Kawamura, K., Tada, Y.,
Ohmori, H., Kimura, H., Sakiyama,
S., and Tagawa, M. (2001). DNA
polymerase kappa, implicated in
spontaneous and DNA damage-
induced mutagenesis, is overex-
pressed in lung cancer. Cancer Res.
61, 5366–5369.
Pages, V., and Fuchs, R. P. (2002).
How DNA lesions are turned into
mutations within cells?Oncogene 21,
8957–8966.
Pan, Q., Fang, Y., Xu, Y., Zhang, K., and
Hu, X. (2005). Down-regulation of
DNA polymerases kappa, eta, iota,
and zeta in human lung, stomach,
and colorectal cancers. Cancer Lett.
217, 139–147.
Rechkoblit, O., Zhang, Y., Guo, D.,
Wang, Z., Amin, S., Krzeminsky, J.,
Louneva, N., and Geacintov, N. E.
(2002). Trans-lesion synthesis past
bulky benzo[a]pyrene diol epoxide
N2-dG and N6-dA lesions catalyzed
by DNA bypass polymerases. J. Biol.
Chem. 277, 30488–30494.
Sakiyama, T., Kohno, T., Mimaki, S.,
Ohta, T., Yanagitani, N., Sobue, T.,
Kunitoh, H., Saito, R., Shimizu, K.,
Hirama, C., Kimura, J., Maeno, G.,
Hirose, H., Eguchi, T., Saito, D.,
Ohki, M., and Yokota, J. (2005).
Association of amino acid substitu-
tion polymorphisms in DNA repair
genes TP53, POLI, REV1 and LIG4
with lung cancer risk. Int. J. Cancer
114, 730–737.
Sancar, A., Lindsey-Boltz, L. A., Unsal-
Kaçmaz, K., and Linn, S. (2004).
Molecular mechanisms of mam-
malian DNA repair and the DNA
damage checkpoints. Annu. Rev.
Biochem. 73, 39–85. [Review].
Scanlon, K. J., Kashani-Sabet, M., and
Miyachi, H. (1989). Differential gene
expression in human cancer cells
resistant to cisplatin. Cancer Invest.
7, 581–587.
Schadt, E. E., Molony, C., Chudin,
E., Hao, K., Yang, X., Lum, P.
Y., Kasarskis, A., Zhang, B., Wang,
S., Suver, C., Zhu, J., Millstein, J.,
Sieberts, S., Lamb, J., GuhaThakurta,
D., Derry, J., Storey, J. D., Avila-
Campillo, I., Kruger, M. J., John-
son, J. M., Rohl, C. A., van Nas,
A., Mehrabian, M., Drake, T. A.,
Lusis, A. J., Smith, R. C., Guen-
gerich, F. P., Strom, S. C., Schuetz,
E., Rushmore, T. H., and Ulrich,
R. (2008). Mapping the genetic
architecture of gene expression in
human liver. PLoS Biol. 6, e107.
doi:10.1371/journal.pbio.0060107.
Sjöblom, T., Jones, S., Wood, L. D., Par-
sons, D. W., Lin, J., Barber, T. D.,
Mandelker, D., Leary, R. J., Ptak, J.,
Silliman, N., Szabo, S., Buckhaults,
P., Farrell, C., Meeh, P., Markowitz,
S. D., Willis, J., Dawson, D., Willson,
J. K., Gazdar, A. F., Hartigan, J., Wu,
L., Liu, C., Parmigiani, G., Park, B.
H., Bachman, K. E., Papadopoulos,
N., Vogelstein, B., Kinzler, K. W., and
Velculescu, V. E. (2006). The con-
sensus coding sequences of human
breast and colorectal cancers. Science
314, 268–274.
Starcevic, D., Dalal, S., and Sweasy, J.
B. (2004). Is there a link between
DNA polymerase beta and cancer?
Cell Cycle. 3, 998–1001. [Review].
Stary, A., Kannouche, P., Lehmann, A.
R., and Sarasin, A. (2003). Role of
DNA polymerase eta in the UV
mutation spectrum in human cells.
J. Biol. Chem. 278, 18767–18775.
Sugo, N., Aratani, Y., Nagashima, Y.,
Kubota, Y., and Koyama, H. (2000).
Neonatal lethality with abnormal
neurogenesis in mice deficient in
DNA polymerase beta. EMBO J. 19,
1397–1404.
Suzuki, N., Ohashi, E., Kolbanovskiy,
A., Geacintov, N. E., Grollman, A.
P., Ohmori, H., and Shibutani, S.
(2002). Translesion synthesis by
human DNA polymerase kappa on
a DNA template containing a single
stereoisomer of dG-(+)- or dG-(–
)-anti-N(2)-BPDE (7,8-dihydroxy-
anti-9,10-epoxy-7,8,9,10-
tetrahydrobenzo[a]pyrene).
Biochemistry 41, 6100–6106.
Sweasy, J. B., Dalal, S., Sun, K. W., Lai, C.
C., DiMaio, D., and Lang, T. (2005).
Expression of DNA polymerase beta
mutants in mouse cells results in
cellular transformation. Proc. Natl.
Acad. Sci. U.S.A. 102, 14350–14355.
Tissier, A., Kannouche, P., Reck, M.
P., Lehmann, A. R., Fuchs, R.
P., and Cordonnier, A. (2004).
Co-localization in replication foci
and interaction of human Y-family
members, DNA polymerase pol eta
and REVl protein. DNA Repair
(Amst.) 3, 1503–1514.
Tissier, A., McDonald, J. P., Frank, E.
G., and Woodgate, R. (2000). Poliota,
a remarkably error-prone human
DNA polymerase. Genes Dev. 14,
1642–1650.
Vaisman, A., and Woodgate, R. (2001).
Unique misinsertion specificity of
poliota may decrease the mutagenic
potential of deaminated cytosines.
EMBO J. 20, 6520–6529.
Velasco-Miguel, S., Richardson, J. A.,
Gerlach, V. L., Lai, W. C., Gao, T.,
Russell, L. D., Hladik, C. L.,White, C.
L., and Friedberg, E. C. (2003). Con-
stitutive and regulated expression of
the mouse Dinb (Polkappa) gene
encoding DNA polymerase kappa.
DNA Repair (Amst.) 2, 91–106.
Wang, Y., Seimiya, M., Kawamura,
K., Yu, L., Ogi, T., Takenaga,
K., Shishikura, T., Nakagawara, A.,
Sakiyama, S., Tagawa, M., and O-
Wang, J. (2004). Elevated expression
of DNA polymerase kappa in human
lung cancer is associated with p53
inactivation: negative regulation of
POLK promoter activity by p53. Int.
J. Oncol. 25, 161–165.
Wang, Y., Woodgate, R., McManus, T.
P., Mead, S., McCormick, J. J., and
Maher, V. M. (2007). Evidence that
in xeroderma pigmentosum variant
cells, which lack DNA polymerase
eta, DNA polymerase iota causes
www.frontiersin.org September 2012 | Volume 3 | Article 174 | 7
Makridakis and Reichardt Translesion DNA polymerases and cancer
the very high frequency and unique
spectrum of UV-induced mutations.
Cancer Res. 67, 3018–3026.
Washington, M. T., Johnson, R. E.,
Prakash, S., and Prakash, L. (2001).
Mismatch extension ability of yeast
and human DNA polymerase eta. J.
Biol. Chem. 276, 2263–2266.
Yang, J., Chen, Z., Liu, Y., Hickey, R. J.,
and Malkas, L. H. (2004). Altered
DNA polymerase iota expression in
breast cancer cells leads to a reduc-
tion in DNA replication fidelity and
a higher rate of mutagenesis. Cancer
Res. 64, 5597–5607.
Yang, J., Parsons, J., Nicolay, N. H.,
Caporali, S., Harrington, C. F., Singh,
R., Finch, D., D’Atri, S., Farmer, P.
B., Johnston, P. G., McKenna, W.
G., Dianov, G., and Sharma, R. A.
(2010). Cells deficient in the base
excision repair protein, DNA poly-
merase beta, are hypersensitive to
oxaliplatin chemotherapy. Oncogene
29, 463–468.
Yasui, M., Suzuki, N., Laxmi, Y. R.,
and Shibutani, S. (2006). Translesion
synthesis past tamoxifen-derived
DNA adducts by human DNA poly-
merases eta and kappa. Biochemistry
45, 12167–12174.
Zhang,Y.,Yuan, F., Wu, X., and Wang, Z.
(2000). Preferential incorporation of
G opposite template T by the low-
fidelity human DNA polymerase
iota. Mol. Cell. Biol. 20, 7099–7108.
Zheng, H., Wang, X., Warren, A. J., Leg-
erski, R. J., Nairn, R. S., Hamilton,
J. W., and Li, L. (2003). Nucleotide
excision repair- and polymerase
eta-mediated error-prone removal
of mitomycin C interstrand cross-
links. Mol. Cell. Biol. 23, 754–761.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or financial relationships that
could be construed as a potential con-
flict of interest.
Received: 23 April 2012; accepted: 20
August 2012; published online: 06 Sep-
tember 2012.
Citation: Makridakis NM and Reichardt
JKV (2012) Translesion DNA poly-
merases and cancer. Front. Gene. 3:174.
doi: 10.3389/fgene.2012.00174
This article was submitted to Frontiers
in Pharmacogenetics and Pharmacoge-
nomics, a specialty of Frontiers in Genet-
ics.
Copyright © 2012 Makridakis and
Reichardt . This is an open-access arti-
cle distributed under the terms of the
Creative Commons Attribution License,
which permits use, distribution and
reproduction in other forums, provided
the original authors and source are cred-
ited and subject to any copyright notices
concerning any third-party graphics
etc.
Frontiers in Genetics | Pharmacogenetics and Pharmacogenomics September 2012 | Volume 3 | Article 174 | 8
